News

Stock Picks : Titan Company Limited And Divis Laboratories Ltd By ICICI Direct Titan Company Limited  Buy Titan Company Limited  @3168-3172; Target 3209.0; Stop Loss 3149.00   Divis Laboratories Ltd Buy Divis Laboratories Ltd @ 3702-3704; Target 3742.00; Stop Loss 3682.00     To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631   Above views are of t...
Stock Picks : Titan Company Limited And Divis Laboratories Ltd By ICICI Direct
Stock Picks : Titan Company Limited And Divis Laboratories Ltd By ICICI Direct
Source: ICICI Direct
7/09/2023 11:12:57 AM
Neutral Divi`s Laboratories Ltd For Target Rs. 3,430 - Motilal Oswal Financial Services Margin recovers; sales yet to pick up Work-in-progress for greenfield project at Kakinada * The operational performance of Divi’s Laboratories (DIVI) missed our estimates marginally in 1QFY24, due to lower sales in generics and custom synthesis. However, EBITDA margin expanded sequentially owing to lower raw material/logistics costs. * We reduce our earnings estimates for FY24/FY25 by 3%/5% to account for a gradual off-take in custom synthesis/nutraceutical sales in the near te...
Neutral Divi`s Laboratories Ltd For Target Rs. 3,430 - Motilal Oswal Financial Services
Neutral Divi`s Laboratories Ltd For Target Rs. 3,430 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
26/08/2023 12:32:53 PM
Stock Picks : Divis Laboratories Ltd and Maruti Suzuki Ltd By ICICI Direct Divis Laboratories (DIVLAB) Ltd  Buy Divis Laboratories (DIVLAB) Ltd @3718-3722; Target 3762.00; Stop Loss 3694.40   Maruti Suzuki Ltd Buy Maruti Suzuki Ltd @ 9320-9325; Target 9252.00; Stop Loss 9366.40     To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631   Above views are...
Stock Picks : Divis Laboratories Ltd and Maruti Suzuki Ltd By ICICI Direct
Stock Picks : Divis Laboratories Ltd and Maruti Suzuki Ltd By ICICI Direct
Source: ICICI Direct
16/08/2023 10:46:13 AM
India`s Divi`s Labs Q1 profit slumps on drug pricing pressures Indian pharmaceutical company Divi's Laboratories reported a 49.2% fall in quarterly profit, missing analysts' estimates, as the generic drug maker grappled with pricing pressures in key markets like the United States. The company reported a consolidated profit of 3.56 billion rupees ($42.9 million) for the first quarter ended June 30, compared to 7.02 billion rupees a year ago. Analysts, on an average, had expected a profit of 4.17 billion rupees, according to Refinitiv data. ...
India`s Divi`s Labs Q1 profit slumps on drug pricing pressures
India`s Divi`s Labs Q1 profit slumps on drug pricing pressures
Source: Reuters
14/08/2023 2:33:00 PM
FII selling streak caps Nifty upside Domestic equities held on to their positive stance despite mixed global cues. Nifty opened higher and remained in positive territory throughout the session to close with marginal gains of 81 points at 19598 levels, says Siddhartha Khemka, Head - Retail Research, Motilal Oswal Financial Services. Majority of the sectors ended in green with buying seen in IT & Pharma. Markets are likely to trade in a range ahead of RBI policy this week, he said. FIIs continued their selling streak for...
FII selling streak caps Nifty upside
FII selling streak caps Nifty upside
Source: IANS
8/08/2023 9:44:08 AM
Stock Picks : Sail and Divis Laboratories By ICICI Direct SAIL Buy Sail Ltd @91.00-91.40; Target 93.00; Stop Loss 90.50   Divis Laboratories Buy Divis Laboratories @ 3675-3679; Target 3724.00; Stop Loss 3654.00     To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631   Above views are of the author and not of the w...
Stock Picks : Sail and Divis Laboratories By ICICI Direct
Stock Picks : Sail and Divis Laboratories By ICICI Direct
Source: ICICI Direct
17/07/2023 10:50:13 AM
Stock Picks : Divis Laboratories Ltd and Ashok Leyland Ltd By ICICI Direct Divis Laboratories Ltd Buy Divis Laboratories Ltd @3532-3536; Target 3576; Stop Loss 3514   Ashok Leyland Ltd Buy Ashok Leyland Ltd @164-164.50; Target 166.80; Stop Loss 162.90   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631   Above v...
Stock Picks : Divis Laboratories Ltd and Ashok Leyland Ltd By ICICI Direct
Stock Picks : Divis Laboratories Ltd and Ashok Leyland Ltd By ICICI Direct
Source: ICICI Direct
27/06/2023 10:40:44 AM
Buy Divi`s Laboratories Ltd For Target Rs.3,575 - ICICI Direct Beat on revenues, below-par margins but worst seems to be over…   About the stock: Divi’s is engaged in manufacturing generic APIs and intermediates, custom synthesis (CS) of active ingredients and advanced intermediates for pharma MNCs, other speciality chemicals like Carotenoids and complex compounds like peptides and nucleotide revenues *  In CS, the company maintains a strong relationship with global big pharma players while in generics it enjoys significan...
Buy Divi`s Laboratories Ltd For Target Rs.3,575 - ICICI Direct
Buy Divi`s Laboratories Ltd For Target Rs.3,575 - ICICI Direct
Source: ICICI Direct
8/06/2023 4:38:32 PM
Stock Picks : Divis Laboratories Ltd and NTPC Ltd By ICICI Direct Divis Laboratories Ltd Buy Divis Laboratories Ltd @3538-3542 CMP 3542.10; Target 3579.00; Stop Loss 3519.00   NTPC Ltd Buy NTPC Ltd @177-177.50 CMP 177.35; Target 179.80; Stop Loss 176.20     To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number IN...
Stock Picks : Divis Laboratories Ltd and NTPC Ltd By ICICI Direct
Stock Picks : Divis Laboratories Ltd and NTPC Ltd By ICICI Direct
Source: ICICI Direct
8/06/2023 12:25:25 PM
Stock Picks : State Bank of India Ltd and Divis Laboratories Ltd By ICICI Direct State Bank of India Ltd Buy State Bank of India Ltd CMP 526.75; Initiation Range 525.50-526.50; Target 533.80; Stop Loss 521.40   Divis Laboratories Ltd Buy Divis Laboratories Ltd CMP 2874.70; Initiation Range 2868-2874; Target 2912.00 ; Stop Loss 2847.00   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number...
Stock Picks : State Bank of India Ltd and Divis Laboratories Ltd By ICICI Direct
Stock Picks : State Bank of India Ltd and Divis Laboratories Ltd By ICICI Direct
Source: ICICI Direct
5/04/2023 10:46:10 AM
Neutral Divis Laboratories Ltd For Target Rs.2,620 - Motilal Oswal Work-in-progress for a better outlook We recently met Divis Laboratories (DIVI) management to understand the business outlook. Below are the key takeaways: * The cost pressures are easing across major factors, indicating improved profitability going forward. * The outlook for contrast media segment remains encouraging, given DIVI’s capability to have better Iodine recovery and limited investment by formulators to manufacture API. * The green-field capital expenditure at Kaki...
Neutral Divis Laboratories Ltd For Target Rs.2,620 - Motilal Oswal
Neutral Divis Laboratories Ltd For Target Rs.2,620 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
20/03/2023 11:59:07 AM
Sell DIVISLAB FUTS For Target RS. 2780 - Religare Broking DIVISLAB Laboratories Ltd * DIVISLAB has been trading in a downward channel since April 2022 and gradually drifting lowe * After the sharp plunged post numbers, it witnessed a marginal rebound, offering a fresh shorting opportunity. * The prevailing negativity in the pharma index is further adding to the confirmation. * We thus suggest creating fresh short positions as per the given levels.  SELL DIVISLAB FUTS CMP (?) 2881.70; Range 2900-2910; SL 2965;&...
Sell DIVISLAB FUTS For Target RS. 2780 - Religare Broking
Sell DIVISLAB FUTS For Target RS. 2780 - Religare Broking
Source: Religare Broking Ltd
24/02/2023 10:52:47 AM
Key Stock News : State Bank of India, Divi's Laboratories Ltd, ITC, Paytm - ARETE Securities Key News SBI Q3 result: Net profit soars 69% YoY to Rs 14,205 crore, beats estimates: State Bank of India (SBI), reported a 68.5% year-on-year surge in net profit for the Q3FY23. The bank reported standalone net profit of Rs 14,205 crore in the recently concluded quarter as against net profit of Rs 8,432 crore in Q3FY22.On a quarter-on-quarter basis, the profit rose 7 % from PAT of Rs 13,265 crore reported in the September quarter of this financial year.SBI's net interest income st...
Key Stock News : State Bank of India, Divi's Laboratories Ltd, ITC, Paytm - ARETE Securities
Key Stock News : State Bank of India, Divi's Laboratories Ltd, ITC, Paytm - ARETE Securities
Source: ARETE Securities Ltd
6/02/2023 9:11:12 AM
Divi`s Labs misses Q3 profit view; shares plunge over 13% BENGALURU - Indian pharmaceutical firm Divi's Laboratories Ltd on Friday reported a third-quarter profit that widely missed analysts' estimates, hurt by higher inventory costs, and sent its shares tumbling more than 13%. The Hyderabad-based company said consolidated net profit for the three months ended Dec. 31 was 3.07 billion rupees ($37.34 million), down from 9.02 billion rupees last year. Analysts on an average had expected the company, which makes drug ingredients, to ...
Divi`s Labs misses Q3 profit view; shares plunge over 13%
Divi`s Labs misses Q3 profit view; shares plunge over 13%
Source: Reuters
3/02/2023 3:11:30 PM
Buy Divi's Laboratories Ltd For Target Rs.4,155 - GEPL Capital Divis Laboratories is the leading manufacturer of APIs (Active pharmaceuticals ingredients), Intermediates and Registered starting materials offering high quality products with the highest level of compliance and integrity. Divi’s quality control testing and validation labs are fitted with state-of-the-art analytical equipment and testing facilities. The company is one of the selected nutraceutical ingredients manufacturers that offer a complete range of carotenoids at a very competitiv...
Buy Divi's Laboratories Ltd For Target Rs.4,155 - GEPL Capital
Buy Divi's Laboratories Ltd For Target Rs.4,155 - GEPL Capital
Source: GEPL Capital Ltd
24/12/2022 10:50:24 AM
Neutral Divi`s Laboratories Ltd For Target Rs.4,340 - Motilal Oswal Financial Miss in 2QFY23; Growth factors to face softness over medium term No visibility yet to the start of the Kakinada project * DIVI delivered an earnings miss in 2QFY23. Reduced traction in Custom Synthesis (CS), coupled with lower operating leverage, resulted in an earnings decline for the first time after 12 quarters of a strong performance. * We cut our FY23/FY24 estimates by 18%, factoring in: a) a deceleration in the CS business and commercial benefit from certain newer projects on c...
Neutral Divi`s Laboratories Ltd For Target Rs.4,340 - Motilal Oswal Financial
Neutral Divi`s Laboratories Ltd For Target Rs.4,340 - Motilal Oswal Financial
Source: Motilal Oswal Financial Services Ltd
19/11/2022 10:10:16 AM
Add Divi`s Laboratories Ltd For Target Rs.3893 - ICICI Securities Margin dips on fall in revenue Divi’s Laboratories’ (Divi’s) Q2FY23 performance was sharply below our estimates. Consolidated revenue fell 6.7% YoY to Rs18.5bn (I-Sec: Rs22.9bn), EBITDA margin slipped 770bps YoY to 33.5% (I-Sec: 41.2%) and adjusted PAT declined 18.6% YoY to Rs4.9bn (I-Sec: Rs6.2bn). Revenue for API division dropped 15.0% YoY while that of custom synthesis division remained flattish. Its strong positioning will help monetise the growth opportunity in API a...
Add Divi`s Laboratories Ltd For Target Rs.3893 - ICICI Securities
Add Divi`s Laboratories Ltd For Target Rs.3893 - ICICI Securities
Source: ICICI Securities
14/11/2022 12:02:29 PM
The key USP of Divi`s is basically the high margins that the company is able to maintain Says Anmol Das, Teji Mandi Below is perspective on Divi`s Laboratories Ltd Quarterly Result by Mr Anmol Das, Head of Research, Teji Mandi 1. Divi's Q2 numbers were a miss both on the revenue front as well as the profit as per the consensus estimates and also lower on a sequential basis. There has been a sharp downtick on net profit at Rs 490 odd crore as compared to Rs 650 crore in the last quarter. The expectation this time around was of QoQ improvement. 2. The key USP of Divi's is basical...
The key USP of Divi`s is basically the high margins that the company is able to maintain Says Anmol Das, Teji Mandi
The key USP of Divi`s is basically the high margins that the company is able to maintain Says Anmol Das, Teji Mandi
Source: PR Agency
8/11/2022 12:40:01 PM
Buy Divi's Laboratories Ltd For Target Rs.4315 - ICICI Direct Near term inflationary pressure; betting on new opportunities in pipeline…   About the stock: Divi’s is engaged in manufacturing generic APIs and intermediates, custom synthesis (CS) of active ingredients and advanced intermediates for pharma MNCs, other speciality chemicals like Carotenoids and complex compounds like peptides and Nucleotide revenues. *  In CS, the company maintains a strong relationship with global big pharma players while in generics it enjoy...
Buy Divi's Laboratories Ltd For Target Rs.4315 - ICICI Direct
Buy Divi's Laboratories Ltd For Target Rs.4315 - ICICI Direct
Source: ICICI Direct
16/08/2022 9:42:53 AM
Buy Divi's Laboratories Ltd For Target Rs.4,340 - Motilal Oswal Financial Short-term hiccups in margin; outlook remains intact * DIVI delivered an in-line earnings in 1QFY23. While traction in Custom Synthesis (CS) has toned down in 1QFY23, there has been a pick-up in the sale of Nutraceuticals. Also, the completion of additional capacity will drive a better sales run-rate in the Generics segment * We cut our FY23/FY24 EPS estimate by 6%/3% to factor in: a) a higher operating cost due to an inflation-linked increase in raw material cost and elevated freight c...
Buy Divi's Laboratories Ltd For Target Rs.4,340 - Motilal Oswal Financial
Buy Divi's Laboratories Ltd For Target Rs.4,340 - Motilal Oswal Financial
Source: Motilal Oswal Financial Services Ltd
15/08/2022 10:08:44 AM
Sell Divi`s Laboratories AUG FUTS For Target Rs.3530 - Religare Broking Religare Super Idea**   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://www.religareonline.com/disclaimer SEBI Registration number is INZ000174330   Views express by all participants are for information & academic purpose only. Kindly read disclaimer before referring below views. Click Here For Disclaimer
Sell Divi`s Laboratories AUG FUTS For Target Rs.3530 - Religare Broking
Sell Divi`s Laboratories AUG FUTS For Target Rs.3530 - Religare Broking
Source: Religare Broking Ltd
27/07/2022 11:30:24 AM
Stock Picks - Divis Laboratories Ltd and Larsen & Toubro Infotech Ltd By ICICI Direct Divis Laboratories Ltd Buy Divis Laboratories Ltd @ 3582.00-3587.00 CMP 3582.90 Stop Loss 3556.30 Target 3609.80/3635.00   Larsen & Toubro Infotech Ltd Buy Larsen & Toubro Infotech Ltd @ 4180.00-4186.00 CMP 4170.00 Stop Loss 4143.70 Target 4218.00/4253.00   To Read Complete Report & Disclaimer Click Here   https://secure.icicidirect.com/Content/StaticData/Disclaimer.html &...
Stock Picks - Divis Laboratories Ltd and Larsen & Toubro Infotech Ltd By ICICI Direct
Stock Picks - Divis Laboratories Ltd and Larsen & Toubro Infotech Ltd By ICICI Direct
Source: ICICI Direct
16/06/2022 9:52:01 AM
Divi`s Laboratories Q4 net profit jumps 80.96% at Rs 882.96 cr The company reported standalone net profit of Rs 882.96 crore for the quarter ended March 31, 2022 as compared to Rs 487.93 crore in the same period last year, registering a year-on-year growth of 80.96 per cent. Net revenue of the company rose substantially by 45.20 per cent at Rs 2,495.03 crore in January-March quarter of this fiscal as against Rs 1,718.39 crore in the corresponding period last year. During January-March quarter, operating expenses increased by 37.29 per cent to Rs 1,399...
Divi`s Laboratories Q4 net profit jumps 80.96% at Rs 882.96 cr
Divi`s Laboratories Q4 net profit jumps 80.96% at Rs 882.96 cr
Source: Dion Global Solutions Ltd
23/05/2022 1:36:02 PM
Stock Picks - Divi's Laboratories And Multi Commodity Exchange By ICICI Direct Divi's Laboratories Buy Divi's Laboratories @ 4500.00-4504.00 CMP 4510.00 Stop Loss 4457.40 Target 1416.6   Multi Commodity Exchange Buy Multi Commodity Exchange @ 1443.00-1445.00 CMP 1444.65 Stop Loss 1458.70 Target 1416.6   To Read Complete Report & Disclaimer Click Here   https://secure.icicidirect.com/Content/StaticData/Disclaimer.html ...
Stock Picks - Divi's Laboratories And Multi Commodity Exchange By ICICI Direct
Stock Picks - Divi's Laboratories And Multi Commodity Exchange By ICICI Direct
Source: ICICI Direct
12/04/2022 10:35:54 AM
Buy Divis Laboratories Ltd For Target Rs. 4800 - Religare Broking Religare Super Idea   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://www.religareonline.com/disclaimer SEBI Registration number is INZ000174330   Views express by all participants are for information & academic purpose only. Kindly read disclaimer before referring below views. Click Here For Disclaimer
Buy Divis Laboratories Ltd For Target Rs. 4800 - Religare Broking
Buy Divis Laboratories Ltd For Target Rs. 4800 - Religare Broking
Source: Religare Broking Ltd
30/03/2022 11:49:59 AM
Stock Picks - Divi's Laboratories​​​​​​​ ​​​​​​​Ltd and Indian Energy Exchange​​​​​​​ Ltd By ICICI Direct Stock Picks Divi's Laboratories Buy Divi's Laboratories Ltd  @ 4460.00-4465.00 CMP 4461.95 TGT 4533.00 SL 4423.70   Indian Energy Exchange​​​​​​​ Buy Indian Energy Exchange​​​​​​​ Ltd @ 221.50-222.50 CMP 219.75 TGT 217.000 SL 224.60     To Read Complete Report & Disclaimer Click Here   https://secure.icicidirect.com/Content/StaticData/Disclaimer...
Stock Picks - Divi's Laboratories​​​​​​​ ​​​​​​​Ltd and Indian Energy Exchange​​​​​​​ Ltd By ICICI Direct
Stock Picks - Divi's Laboratories​​​​​​​ ​​​​​​​Ltd and Indian Energy Exchange​​​​​​​ Ltd By ICICI Direct
Source: ICICI Direct
17/02/2022 10:21:07 AM
Buy Divi's Laboratories Ltd For Target Rs.5,500 - Motilal Oswal Custom Synthesis drives earnings Promising outlook, with superior execution, bodes well for company * Divi’s Lab (DIVI) delivered a strong beat on 3QFY22 earnings, led by healthy growth across the Custom Synthesis (CS), API, and Nutraceutical businesses. DIVI continues its efforts in strengthening its chemistry skill set and manufacturing capacity for COVID / non-COVID business. * We raise our FY22E earnings by 8% to factor in a higher off-take in the CS segment. We mainta...
Buy Divi's Laboratories Ltd For Target Rs.5,500 - Motilal Oswal
Buy Divi's Laboratories Ltd For Target Rs.5,500 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
14/02/2022 11:07:35 AM
Divi's Laboratories rises on reporting 92% rise in Q3 consolidated net profit Divi's Laboratories is currently trading at Rs. 4334.10, up by 20.70 points or 0.48% from its previous closing of Rs. 4313.40 on the BSE. The scrip opened at Rs. 4300.55 and has touched a high and low of Rs. 4475.00 and Rs. 4240.60 respectively. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 5,425.00 on 18-Oct-2021 and a 52 week low of Rs. 3,154.50 on 19-March-2021. Last one week high and low of the scrip stood at Rs. 4475.00 and Rs. 4164.9...
Divi's Laboratories rises on reporting 92% rise in Q3 consolidated net profit
Divi's Laboratories rises on reporting 92% rise in Q3 consolidated net profit
Source: Accord Fintech
11/02/2022 2:50:33 PM
Buy Divi's Laboratories Ltd For Target Rs.4780 - Religare Broking Religare Super Idea   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://www.religareonline.com/disclaimer SEBI Registration number is INZ000174330   Above views are of the author and not of the website kindly read disclaime
Buy Divi's Laboratories Ltd For Target Rs.4780 - Religare Broking
Buy Divi's Laboratories Ltd For Target Rs.4780 - Religare Broking
Source: ICICI Direct
30/12/2021 11:54:45 AM
Buy Divi's Laboratories Ltd For Target Rs.5600 - ICICI Direct Custom synthesis drive numbers; generics muted… About the stock: Divi’s is engaged in manufacturing generic APIs and intermediates, custom synthesis (CS) of active ingredients and advanced intermediates for pharma MNCs, other speciality chemicals like Carotenoids and complex compounds like peptides and Nucleotide revenues. * In CS, the company maintains strong relationship with global big pharma players while in generics it enjoys significant market share in products like N...
Buy Divi's Laboratories Ltd For Target Rs.5600 - ICICI Direct
Buy Divi's Laboratories Ltd For Target Rs.5600 - ICICI Direct
Source: ICICI Direct
20/12/2021 10:02:38 AM
Stock Picks - Divi's Laboratories Ltd and Amara Raja Batteries Ltd By ICICI Direct Divi's Laboratories Buy Divi's Laboratories Ltd @ 4798.00-4802.00 CMP 4812.80 TGT 4895.20 SL 4749.40   Amara Raja Batteries Sell Amara Raja Batteries Ltd @ 625.00-627.00 CMP 627.00 TGT 620.30 SL 632.50   To Read Complete Report & Disclaimer Click Here   https://secure.icicidirect.com/Content/StaticData/Disclaimer.html   Views express by all part...
Stock Picks - Divi's Laboratories Ltd and Amara Raja Batteries Ltd By ICICI Direct
Stock Picks - Divi's Laboratories Ltd and Amara Raja Batteries Ltd By ICICI Direct
Source: ICICI Direct
26/11/2021 11:26:59 AM
India's Divi's Labs hits record high on Merck's positive trial data for COVID-19 drug BENGALURU - Shares of India's Divi's Laboratories Ltd, which makes the main ingredient of Merck & Co's experimental antiviral pill, soared 10% on Monday, after the pharmaceutical giant reported positive clinical trial results for the drug. Global drugmaker Merck and partner Ridgeback Biotherapeutics on Friday said molnupiravir could halve the chances of dying or being hospitalised for those most at risk of contracting severe COVID-19, according to the data released by ...
India's Divi's Labs hits record high on Merck's positive trial data for COVID-19 drug
India's Divi's Labs hits record high on Merck's positive trial data for COVID-19 drug
Source: Reuters
4/10/2021 12:29:40 PM
Hold Divi`s Laboratories Ltd For Target Rs.4,828 - ICICI Securities Margins surprised positively Divi’s Laboratories (Divis) reported Q1FY22 performance broadly in line with estimates though EBITDA margin beat estimate by 230bps. Consolidated revenue grew 13.3% YoY to Rs19.6bn (I-Sec: Rs20.0bn), EBITDA margin improved 300bps YoY to 43.5% (I-sec: 41.2%) and PAT grew 13.2% to Rs5.6bn (I-sec: Rs5.8bn). The growth was driven primarily by custom synthesis business with generics declining YoY due to general quarterly volatility. Strong positioning of Di...
Hold Divi`s Laboratories Ltd For Target Rs.4,828 - ICICI Securities
Hold Divi`s Laboratories Ltd For Target Rs.4,828 - ICICI Securities
Source: ICICI Securities
29/09/2021 10:56:06 AM
Buy Divi`s Laboratories Ltd For Target Rs.5815 - ICICI Direct Strong Q1 on all fronts… About the stock: Divi’s is engaged in manufacturing of generic APIs and intermediates, custom synthesis of active ingredients and advanced intermediates for pharma MNCs, other speciality chemicals like Carotenoids and complex compounds like peptides and Nucleotide revenues. * It has six manufacturing units & three R&D centres & offers 122 products * Custom synthesis business is a high margin one but at times lumpy as it depends on off...
Buy Divi`s Laboratories Ltd For Target Rs.5815 - ICICI Direct
Buy Divi`s Laboratories Ltd For Target Rs.5815 - ICICI Direct
Source: ICICI Direct
29/09/2021 10:17:53 AM
Investment Idea : Buy Divi`s Laboratories Ltd For Target Rs.5,750 - Motilal Oswal Building ‘growth engines’ for sustainable earnings momentum DIVI, an Indian Pharma company, is among the top three API manufacturers in the world. It is also into manufacturing of Nutraceutical ingredients and Custom synthesis (CS) of APIs for global Pharma MNCs. Scale-up in legacy products and new introductions to drive growth in the Generic API segment: DIVI has had a successful track record, with a leading market share in the supply of large volume APIs, on the ba...
Investment Idea : Buy Divi`s Laboratories Ltd For Target Rs.5,750 - Motilal Oswal
Investment Idea : Buy Divi`s Laboratories Ltd For Target Rs.5,750 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
13/09/2021 12:04:21 PM
Buy Divi`s Laboratories Ltd For Target Rs.5,750 - Motilal Oswal Yet another consistent quarter despite industry headwinds Building ‘growth engines’ for sustainable earnings momentum * Divi’s Labs (DIVI) delivered in-line 1QFY22 earnings, led by strong off-take in the Custom Synthesis (CS) segment. The backward integration efforts over the past 2–3 years have fructified at a time when peers are facing issues in terms of raw material and logistics cost increases. In fact, this has led to better profitability for the quarter. DI...
Buy Divi`s Laboratories Ltd For Target Rs.5,750 - Motilal Oswal
Buy Divi`s Laboratories Ltd For Target Rs.5,750 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
10/09/2021 9:57:12 AM
Buy Divi`s Laboratories Ltd For Target Rs.6,070 - Motilal Oswal Six cylinder growth engine * DIVI is a strong player in Generic APIs, with a market leading position for ~60% of its portfolio of ~30 molecules. In Custom Synthesis (CS), it works with innovators and big Pharma companies right from the clinical stage to commercial production. * It is working on 16 new molecules in Generic APIs, which are at various stages of development and will provide new growth opportunities in this segment. Capex of ~INR7b and new capex of ~INR6b at the Kakinada sit...
Buy Divi`s Laboratories Ltd For Target Rs.6,070 - Motilal Oswal
Buy Divi`s Laboratories Ltd For Target Rs.6,070 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
4/09/2021 10:05:49 AM
Key News - Steel Authority of India Ltd, BSE , Hindalco Industries Ltd, JK Tyre & Industries Ltd, Divi's Laboratories Ltd, Bank of Baroda By ARETE Securities Key News SAIL returns to black; posts Rs 3,897-cr net profit for June quarter Domestic steel major SAIL on Friday returned to the black, posting a consolidated net profit of Rs 3,897.36 crore for the June 2021 quarter. The company had posted a Rs 1,226.47-crore net loss in the year-ago quarter, Steel Authority of India Ltd (SAIL) said in a BSE filing. Its net income during April-June 2021 more than doubled to Rs 20,754.75 crore, compared with Rs 9,346.21 crore in the year-ago period. To...
Key News - Steel Authority of India Ltd, BSE , Hindalco Industries Ltd, JK Tyre & Industries Ltd, Divi's Laboratories Ltd, Bank of Baroda By ARETE Securities
Key News - Steel Authority of India Ltd, BSE , Hindalco Industries Ltd, JK Tyre & Industries Ltd, Divi's Laboratories Ltd, Bank of Baroda By ARETE Securities
Source: ARETE Securities Ltd
9/08/2021 8:54:21 AM
Buy Divi`s Laboratories Ltd For Target Rs. 4,825 - ICICI Direct Strong growth outlook backed by execution… Q4 revenues grew 28.7% YoY to | 1788 crore (I-direct estimate: | 1743 crore). Generic segment grew 24.8% YoY to | 917 crore. Custom synthesis grew 25.5% YoY to | 715 crore. Carotenoids grew 83.5% YoY to | 156 crore. EBITDA margins expanded 807 bps YoY to 40.1% (I-direct estimates: 39.0%) due to better gross margin performance (up 458 bps YoY to 67.5%) and lower other expenditure. EBITDA grew 61.2% YoY to | 716 crore (I-direct estimate: | 68...
Buy Divi`s Laboratories Ltd For Target Rs. 4,825 - ICICI Direct
Buy Divi`s Laboratories Ltd For Target Rs. 4,825 - ICICI Direct
Source: ICICI Direct
28/06/2021 11:05:42 AM
Add Divis Laboratories Ltd For Target Rs. 4,436 - ICICI Securities Strong performance continues Divi’s Laboratories (Divis) reported Q4FY21 performance marginally higher than our estimates. Consolidated revenue grew 28.7% YoY to Rs17.9bn (I-Sec: Rs17.0bn), EBITDA margin improved 810bps YoY to 40.1% (I-sec: 40.5%) and PAT grew 29.3% to Rs5.0bn (I-sec: Rs4.9bn). The growth was driven across generic APIs and CRAMS businesses. Strong positioning of Divis will help in monetising the growth opportunity in API and CRAMS space given its stellar execution...
Add Divis Laboratories Ltd For Target Rs. 4,436 - ICICI Securities
Add Divis Laboratories Ltd For Target Rs. 4,436 - ICICI Securities
Source: ICICI Securities Ltd
26/06/2021 9:28:25 AM
Buy Divi`s Laboratories Ltd For Target Rs. 4,850 - Motilal Oswal On a stellar growth trajectory Multiple levers across Custom Synthesis/API/Nutraceuticals space * DIVI delivered in line 4QFY21 earnings. It ended FY21 on a strong note, with 29%/57%/54% YoY growth in sales/EBITDA/PAT. New product development, ongoing capex, and strong prospects in Custom Synthesis (CS) provides confidence that the momentum in earnings growth will sustain over the next 2-3 years. * We have raised our FY22E/FY23E EPS estimate by 4% each to reflect: a) scale-up in CS p...
Buy Divi`s Laboratories Ltd For Target Rs. 4,850 - Motilal Oswal
Buy Divi`s Laboratories Ltd For Target Rs. 4,850 - Motilal Oswal
Source: Motilal Oswal Financial Services
22/06/2021 9:59:19 AM
Key News - Divi`s Laboratories Ltd, Bank of Baroda, Mahindra and Mahindra Ltd, Glenmark Pharmaceuticals Ltd, Max Healthcare Institute Ltd by ARETE Securities Key News Divi's Labs Q4 net profit jumps 29% at Rs 502 crore on robust sales Drug firm Divi's Laboratories on Saturday reported a 29.30 percent rise in its consolidated net profit to Rs 502.02 crore for the quarter ended March 31, 2021, on account of robust sales. The company had posted a net profit of Rs 388.23 crore for the corresponding period of the previous fiscal, Divi's Laboratories said in a regulatory filing. Consolidated total income of the company stood at Rs 1,81...
Key News - Divi`s Laboratories Ltd, Bank of Baroda, Mahindra and Mahindra Ltd, Glenmark Pharmaceuticals Ltd, Max Healthcare Institute Ltd by ARETE Securities
Key News - Divi`s Laboratories Ltd, Bank of Baroda, Mahindra and Mahindra Ltd, Glenmark Pharmaceuticals Ltd, Max Healthcare Institute Ltd by ARETE Securities
Source: ARETE Securities Ltd
31/05/2021 9:21:45 AM
Trilogy for the month : Prince Pipes and Fittings Ltd, Divi`s Laboratories Ltd, Carborundum Universal Ltd By LKP Securities PRINCE PIPES AND FITTINGS LTD * Stock has given a bullish pennant breakout on daily chart which is consider to be a bullish continuation pattern by nature. * Strong volume activity has been seen at the time of breakout. * Prices are well managing above ichimoku clouds which hint overall trend is good . PRINCE PIPES AND FITTINGS LTD @528-532 CMP 528 1 MONTH TARGET 600 SL 500 CB   DIVI'S LABORATORIES LTD * Stock has given fresh bre...
Trilogy for the month : Prince Pipes and Fittings Ltd, Divi`s Laboratories Ltd, Carborundum Universal Ltd By LKP Securities
Trilogy for the month : Prince Pipes and Fittings Ltd, Divi`s Laboratories Ltd, Carborundum Universal Ltd By LKP Securities
Source: LKP Securities Ltd
3/05/2021 9:52:42 AM
Stock Picks - Divis Laboratories Ltd and Divis Laboratories Ltd By ICICI Direct Divis Laboratories Buy Divis Laboratories Ltd @ 3917.00-3923.00. CMP 3917.35 TGT 3980.00 SL 3887.80   Tata Chemical Buy Tata Chemical Ltd @ 761.00-763.00. CMP 761.40 TGT 776.00 SL 754.40   To Read Complete Report & Disclaimer Click Here   https://secure.icicidirect.com/Content/StaticData/Disclaimer.html   Views express by all participants...
Stock Picks - Divis Laboratories Ltd and Divis Laboratories Ltd By ICICI Direct
Stock Picks - Divis Laboratories Ltd and Divis Laboratories Ltd By ICICI Direct
Source: ICICI Direct
28/04/2021 11:39:20 AM
Buy Divi`s Laboratories Limited Target Rs. 4100 - Religare Broking Religare Super Idea   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer http://ex.religareonline.com/disclaimer SEBI Registration number is INZ000174330 Above views are of the author and not of the website kindly read disclaimer
Buy Divi`s Laboratories Limited Target Rs. 4100 - Religare Broking
Buy Divi`s Laboratories Limited Target Rs. 4100 - Religare Broking
Source: Religare Broking Ltd
28/04/2021 10:23:28 AM
Stock Picks - Divis Laboratories Ltd and PVR Ltd By ICICI Direct Divis Laboratories Buy Divis Laboratories Ltd @ 3754.00-3760.00 CMP 3767.55 TGT 3786.90 SL 3726.40   PVR Ltd Sell PVR Ltd @ 1145.00-1149.00 CMP 1149.00 TGT 1137.10 SL 1157.20   To Read Complete Report & Disclaimer Click Here   https://secure.icicidirect.com/Content/StaticData/Disclaimer.html   Above views are of the author and not of the website kindly read disclaimer
Stock Picks - Divis Laboratories Ltd and PVR Ltd By ICICI Direct
Stock Picks - Divis Laboratories Ltd and PVR Ltd By ICICI Direct
Source: ICICI Direct
12/04/2021 12:13:17 PM
Stock Picks - Titan Ltd and Divi`s Laboratories Ltd By ICICI Direct Titan Buy Titan Ltd @ 1528.00-1533.00 CMP 1537.45 TGT 1560.00 SL 1515.10   Divi’s Laboratories Buy Divi’s Laboratories Ltd @ 3710.00-3716.00 CMP 3712.85 TGT 3773.00 SL 3681.80   To Read Complete Report & Disclaimer Click Here   https://secure.icicidirect.com/Content/StaticData/Disclaimer.html   Above views are of the author and not of the website kindly read disclaimer
Stock Picks - Titan Ltd and Divi`s Laboratories Ltd By ICICI Direct
Stock Picks - Titan Ltd and Divi`s Laboratories Ltd By ICICI Direct
Source: ICICI Direct
7/04/2021 12:59:03 PM
Buy Divi`s Laboratories Ltd For Target Rs.4,530 - Motilal Oswal WIP in niche areas for sustained growth momentum * Divi’s Labs (DIVI), in addition to having a robust base business, is enhancing its product offerings in the generic API space – at least sixteen molecules are under various phases of development and in the subsequent DMF filing stage. * Particularly, we find DIVI’s work interesting in the Contrast Media segment. While there is complexity associated with Iodine-based products, DIVI’s strong chemistry skill set an...
Buy Divi`s Laboratories Ltd For Target Rs.4,530 - Motilal Oswal
Buy Divi`s Laboratories Ltd For Target Rs.4,530 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
25/03/2021 9:27:31 AM